The emerging standard of care for patients with inoperable pancreatic cancer is a combination of cytotoxic drugs gemcitabine and Abraxane, but patient response remains moderate. Pancreatic cancer development and metastasis occur in complex settings, with reciprocal feedback from microenvironmental cues influencing both disease progression and drug response. Little is known about how sequential dual targeting of tumor tissue tension and vasculature before chemotherapy can affect tumor response. We used intravital imaging to assess how transient manipulation of the tumor tissue, or "priming," using the pharmaceutical Rho kinase inhibitor Fasudil affects response to chemotherapy. Intravital Förster resonance energy transfer imaging of a cyclin-dependent kinase 1 biosensor to monitor the efficacy of cytotoxic drugs revealed that priming improves pancreatic cancer response to gemcitabine/Abraxane at both primary and secondary sites. Transient priming also sensitized cells to shear stress and impaired colonization efficiency and fibrotic niche remodeling within the liver, three important features of cancer spread. Last, we demonstrate a graded response to priming in stratified patient-derived tumors, indicating that fine-tuned tissue manipulation before chemotherapy may offer opportunities in both primary and metastatic targeting of pancreatic cancer.
INTRODUCTION
A number of new therapeutics have been exploited to improve upon gemcitabine (Gem) in pancreatic cancer (PC). Recently, the addition of nab-paclitaxel (Abraxane) to Gem improved patient survival from 6.6 to 8.7 months (1) . Although the improvements found with the antimitotic Abraxane are encouraging and the combination is rapidly becoming a first-line treatment in this aggressive disease (2) , there is an urgent need to improve upon this moderate shift in patient survival.
The actin cytoskeleton and its prototypical regulatory proteins Rho guanosine triphosphatases (GTPases) are commonly hijacked by many cancers to drive tumor progression (3) (4) (5) (6) . In particular, altering cytoskeleton-based cell contractility affects not only coordinated cancer cell protrusion during invasion but also the bidirectional interaction between stromal and cancer cells to induce tissue stiffening and drive tumor survival, proliferation, and progression (7) (8) (9) (10) . Hence, targeting tissue architecture via Rho GTPase inhibition to alter tissue stiffness, cellular rheology, vasodilation, or mechanoplasticity is an emerging area of potential therapeutic intervention in cancer (3, 5, (11) (12) (13) (14) .
Optimizing preclinical disease models in drug discovery requires innovative approaches to assess drug response in live tissue at the singlecell and molecular levels. Intravital imaging offers insights into how cells behave in their native environment and provides a dynamic fourdimensional (4D) molecular readout of therapeutic response, undetectable in vitro (15, 16) . Here, we derived primary and invasive cells from both the Pdx1-Cre, LSL-Kras G12D/+ , LSL-Trp53 R172H/+ (KPC) mouse model (17) (18) (19) (20) (21) and pancreatic patient-derived xenografts (PDXs) and engineered them to express the highly validated cyclin-dependent kinase 1 (CDK1) Förster resonance energy transfer (FRET) biosensor (22, 23) . We monitored CDK1 activity as a surrogate marker of M-phase cell cycle arrest induced by Gem/Abraxane (22) (23) (24) (25) (26) (27) . Upon investigating the ultrastructure, integrity, and stiffness of the extracellular matrix (ECM) in complex organotypic matrices in response to transient priming with the ROCK inhibitor Fasudil (HA-1077) (28) , we mapped PC cell response to Gem/Abraxane in live tumor tissues during disease progression. First, this was achieved through spatiotemporal monitoring of the response to Gem/Abraxane at distinct sites within live primary tumors and PDXs, whereas assessment in liver metastases revealed a multisite improvement in response to chemotherapy after transient dual manipulation of tissue tension and tumor vasculature with Fasudil. Second, priming impaired tumor cell extravasation efficiency, resistance to shear stress, and metastatic niche remodeling within the liver, reducing spread in secondary sites. Last, we reveal a graded response to transient priming regimens relative to ECM found in PDXs from the Australian Pancreatic Cancer Genome Initiative (APGI) cohort (29) . Collectively, we present preclinical evidence that tailored, fine-tuned tissue priming before chemotherapy may offer opportunities in both primary and metastatic targeting in PC.
RESULTS

Priming the stroma via ROCK inhibition disrupts ECM integrity
The effect of ROCK inhibition on ECM integrity was assessed using fibroblast-driven contraction assays, which revealed a decrease in contraction upon treatment with Fasudil (Fig. 1A) . Immunohistochemical (IHC) analysis of ROCK signaling in matrices confirmed that Fasudil inhibits the downstream targets of ROCK, pMLC2, and pMYPT1 (fig. S1, A and B) (30) , whereas 2D and 3D cell proliferation analyses indicated that impairment of matrix contraction was independent of changes in fibroblast proliferation and survival (fig. S1, C to E).
Second harmonic generation (SHG) imaging (31) and polarized light microscopy of picrosirius red staining (32, 33) of contracted collagen matrices revealed a reduction in fibrillar collagen coverage upon ROCK inhibition compared to control (Fig. 1 , B to D, and fig. S1F), whereas collagen production was unaltered ( Fig. 1 , E and F). Live monitoring of fibroblast-ECM interactions ( Fig. 1G and movie S1) (34) demonstrated uncoordinated, shorter, and unstable fibroblast protrusions in Fasudil-treated conditions, as well as increased cell circularity (Fig. 1H) . Analysis of matrix ultrastructure using gray-level cooccurrence matrix (GLCM) (35) and scanning electron microscopy confirmed a disorganized ECM network in Fasudil-treated condition ( Fig. 1, I to K), and atomic force microscopy measurements revealed a reduction in matrix stiffness for primed matrices (Fig. 1L) . Similar results were observed for matrices treated with the structurally unrelated ROCK inhibitor Y-27632 (fig. S1, G to L), confirming that ROCK targeting disrupts matrix integrity.
Recent studies assessing the effect of stromal manipulation via longterm interference with ECM remodeling have yielded conflicting data on the utility of stromal targeting in limiting the progression of PC (10, 12, (36) (37) (38) (39) (40) (41) (42) (43) . We therefore sought to assess whether fine-tuned transient interference with stromal tension affects PC progression and drug response (10) .
The scheduling of priming regimens influences PC cell invasion and Gem/Abraxane efficacy We examined cancer cell invasion in a 3D organotypic model using primary PC cells established from KPC mice (17, 18, 44, 45) . 3D organotypic matrices were treated with Fasudil either during contraction (priming) or during invasion (later treatment) ( Fig. 2A) . KPC cell invasion was decreased in matrices primed with Fasudil compared to control (Fig. 2 , B and C). Later Fasudil treatment alone did not significantly affect KPC invasion, and continuous treatment during both contraction and invasion had no advantage over priming of the matrix alone (Fig. 2 , B and C), demonstrating that transient ROCK targeting can impair PC invasion and could minimize the need for long-term treatments.
Because mechanical cues provided by the ECM have been suggested to limit response to chemotherapy (46, 47) , we next investigated whether transient Fasudil priming would increase KPC cell response to subsequent Gem/Abraxane treatment in organotypic matrices. Ki67 and cleaved caspase-3 staining demonstrated that Gem/Abraxane treatment alone reduced cell proliferation and induced cell apoptosis (Fig. 2, D and E, black bars versus green bars), as expected given their clinical use (2) . This was improved in Fasudil-primed settings (Fig. 2, D and E, green bars versus blue bars), although Fasudil priming alone had no effect on KPC cell proliferation and apoptosis in this context (Fig. 2, D and E, black bars versus orange bars).
Although these static markers of tumor behavior provide an initial insight into tumor response, they lack the capacity to monitor more detailed temporal and spatial information. We therefore opted to longitudinally map Gem/Abraxane therapy using a CDK1-FRET biosensor (22, 23) as a molecular readout of cell cycle arrest induced by chemotherapy (27) .
A CDK1 biosensor monitors PC cell response to Gem/Abraxane Primary KPC cells were engineered to express a CDK1-FRET biosensor, and the activity of CDK1 was measured by fluorescence lifetime imaging microscopy of the FRET signal (FLIM-FRET; Fig. 3A ). In the lifetime color maps, low CDK1 activity is represented by longer lifetimes and yellow/red colors, whereas high CDK1 activity is represented by shorter lifetimes and blue/green colors, and areas with no signal are black ( Fig. 3B and fig. S2A ).
To confirm that the CDK1-FRET biosensor reports changes in CDK1 activity, KPC cells were treated with Abraxane to arrest them in mitosis, where CDK1 activity is high (22) (23) (24) (25) (26) (27) , followed by treatment with the specific CDK1 inhibitor RO3306 ( fig. S2 , B and C) (48) . Abraxane induced a decrease in the fluorescence lifetimes, indicating active CDK1, and treatment with RO3306 reverted the lifetimes to values similar to control, confirming CDK1 inhibition ( fig. S2 , C and D, and movie S2). Using the lifetime distribution, we stratified cells as "CDK1 ON" or "CDK1 OFF" and confirmed changes in CDK1 activity by Western blot analysis of pY15-CDK1 ( fig. S2, E and F) . Similarly, FLIM-FRET analysis of cells in different stages of the cell cycle confirmed accumulation of active CDK1 in mitotic cells compared to cells in interphase ( fig. S2 , G to I, and movie S3). We also confirmed that expression of the CDK1 (G) Time-lapse tracking of fibroblast-ECM interactions on day 6 of contraction ± Fasudil and color-coded overlay of single protrusion tracking (red, t = 0 min; light green, t = 100 min; yellow, t = 200 min; blue, t = 300 min; dark green, t = 400 min; purple, t = 500 min). Scale bars, 100 mm. invasion (50) (51) (52) (53) . Hence, we assessed CDK1 activity in cells invading into the matrix versus cells on top of the matrix over time (Fig. 3 , C to E, and movie S4). For cells on top of the matrix, we observed a decrease in FRET lifetime and corresponding activation of CDK1 after 16 hours of treatment with Gem/Abraxane. This was sustained for 24 hours and then reverted to higher lifetimes at 48 hours (Fig. 3D , purple line). An earlier activation of CDK1 in matrices that had been primed with Fasudil was evident after 8 hours of Gem/Abraxane treatment, and the 
Proliferative, noninvading cells (top matrix, <30 µm)
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Vennin et al., Sci. Transl. Med. 9, eaai8504 (2017) 5 April 2017activation of CDK1 was prolonged (Fig. 3D , orange line). Monitoring of CDK1 at depth demonstrated a distinctly delayed pattern of response to Gem/Abraxane in invading cells (compare the purple line in Fig. 3D to that in Fig. 3E ); however, Fasudil priming increased the response of invasive cells at later time points compared to Gem/Abraxane treatment alone (Fig. 3E ). The ability to detect differences in drug efficacy in a spatial manner allowed us to uncover that proliferating cells on top of the matrix respond well to Gem/Abraxane therapy alone, whereas invading and less proliferative cells (confirmed in fig. S2M ) (50) are less susceptible to cytotoxic drugs. Thus, although Fasudil interference with stromatumor feedback improves targeting of cells on top of the matrix, it may also have additional, yet somewhat delayed, benefits by rendering invasive cells more vulnerable to chemotherapy.
Priming live primary tumors enhances Gem/Abraxane efficacy We next generated subcutaneous KPC-CDK1 xenografts, and once primary tumors were palpable, mice were primed with Fasudil for 3 days before treatment with Gem/Abraxane (Fig. 4A ). Twenty-four hours after administration of Gem/Abraxane, live tumor tissues were exposed using a skin flap technique for intravital imaging (Fig. 4B ). SHG imaging and polarized light microscopy of picrosirius red staining of KPC xenografts confirmed that Fasudil priming reduces fibrillar collagen organization in this setting, whereas no significant change in collagen content was observed ( To assess whether ECM-independent mechanisms may also play a role in the enhanced response to chemotherapy, we examined the known role of Fasudil as a vasodilator in vivo (28) by evaluating vasculature abundance using anti-CD31 staining. This demonstrated an increase in CD31-positive cells upon treatment with Fasudil (Fig. 4F) . We next injected quantum dots into mice bearing subcutaneous KPC tumors to assess whether vascular patency was altered in Fasudiltreated conditions (39, 54) . Here, an increase in quantum dot signal was observed outside blood vessels, with quantum dots leaking into the tumor tissue in Fasudil-primed conditions compared to control (Fig. 4 , G and H, and movie S7). Because PC patients often present with locally invasive and metastatic disease at diagnosis (55), we next investigated whether Fasudil priming alone or in combination with chemotherapy alters metastatic colonization of secondary sites.
Priming with Fasudil enhances chemotherapy response at secondary sites and reduces metastatic spread To mimic systemic ROCK inhibition or adjuvant therapy in the presence of circulating tumor cells, we performed intrasplenic injections of KPC cells expressing the CDK1-FRET biosensor in parallel with Fasudil administration (Fig. 5, A and B, and movie S8). FLIM-FRET measurements of the CDK1 biosensor in liver metastases revealed that priming with Fasudil enhanced Gem/Abraxane efficacy at this secondary site (Fig. 5 , C to E). In line with our results in primary tumors (Fig. 4) , we observed enhanced CD31 staining and increased number of microvessels with detectable lumens in the livers of Fasudil-treated mice ( Fig.  5F and fig. S4A ), which could partly explain the observed enhanced drug response. Pathological and IHC analyses on serial sections of metastases (Fig. 5 , G and H) confirmed that mice treated with Fasudil and Gem/Abraxane showed a marked reduction in metastatic spread compared to Gem/Abraxane treatment alone. This is in line with recent work regarding the establishment of the metastatic niche (56, 57) and prompted us to assess micrometastatic events, such as cancer cell extravasation, adhesion, response to shear stress, and colonization after Fasudil priming.
Priming hinders extravasation and spread in the liver while sensitizing cells to shear stress and reducing anchorage-independent growth To identify pancreatic tumor cells that had recently extravasated in the liver and breached the matrix surrounding blood vessels, we stained liver tissues with Elastica van Gieson and PDX-1 (Fig. 6, A and B) . Quantification of extravasation events revealed that priming with Fasudil impaired extravasation compared to control and Gem/Abraxane treatment (Fig. 6 , A to C), suggesting that Fasudil may act as a potential antiadhesion drug. This mirrors recent work showing that targeting early "homing" events in the liver using anti-adhesion drugs can have additional advantages over cytotoxic targeting alone (58, 59) . To address the anti-adhesion effect of Fasudil in a more controlled platform, we used cell-derived matrices (CDMs) (60, 61 S4E ) revealed a marked reduction in KPC cell adhesion in Fasudilprimed conditions over time compared to control and Gem/Abraxane counterparts (Fig. 6E , compare black and orange lines). In addition, the cytotoxic effects of Gem/Abraxane combined with Fasudil's anti-adhesion effect increased the reduction in KPC attachment and viability (Fig. 6E , compare green to blue lines at 24 hours). This was in line with FLIM-FRET analysis of CDK1 on CDMs and in the liver in vivo (Fig. 5C and fig. S4F ), where Fasudil priming enhanced response to Gem/Abraxane. To further assess the observed reduction of liver colonization upon Fasudil priming, we examined the viability of cells in response to shear stress and anchorage-independent growth (AIG), which circulating tumor cells are subjected to in vivo. KPC cells were primed with Fasudil and exposed to controlled shear stress as previously described (Fig. 6F) (62) and then plated on CDMs to measure their ability to attach, survive, or proliferate after shear stress. Cell attachment on CDMs and cell growth were reduced upon treatment with Fasudil, with a concomitant increase in apoptosis (Fig. 6G) , as confirmed by FACS analyses (Fig.  6H ). These data, along with reduced long-term AIG in Fasudil-primed conditions (Fig. 6I ), point to a role of ROCK inhibition in sensitizing cells to shear stress in the systemic circulation and suggest an additional way in which Fasudil can impinge on metastasis in PC (10, 13, 63, 64) .
Fasudil priming reduces cell streaming and metastatic niche remodeling To assess whether priming with Fasudil affects KPC cell movement, we performed time-lapse monitoring of KPC cell streaming on CDMs primed with or without Fasudil and quantified cell movement anisotropy as a readout of coordinated cell movement ( Fig. 7A and movie S9) (65) . In control conditions, concerted streams of cells moving in a coordinated, organized manner were observed (Fig. 7A , green arrows) (65, 66) . This was reduced in cells seeded on Fasudil-primed matrices, where noncoordinated cell movement was evident over time (Fig. 7, A  and B) , and was further supported by a clear decrease in cell stream width compared to control (Fig. 7C) . We next studied whether Fasudil priming altered metastatic spread patterns in the liver using IHC analysis of PDX-1-stained serial sections. Here, we observed different effectiveness in the liver (Fig. 5 , C to E), we assessed the ability of KPC cells to remodel the ECM upon priming with Fasudil. Using CDMs as a model system, we found that KPC cells can remodel the matrix of unprimed CDMs, as measured by increased SHG signal over time (Fig. 7, F 
Vennin et al., Sci. Transl. Med. 9, eaai8504 (2017) 5 April 2017significantly increase after seeding of KPC cells (Fig. 7, F and G, blue  lines) . Moreover, KPC cell protrusions on primed CDMs were also disrupted compared to control ( fig. S4 , G to I), in line with earlier observations, and this prompted us to assess the amount of fibrillar collagen within liver metastases. Here, we found that remodeling of the metastatic niche was impaired upon priming with Fasudil (Fig. 7, H to K, and fig.  S4J ). Hence, priming may make secondary tissues less permissive to the establishment of metastases and expose cancer cells to a less favorable environment (67) . This may partly explain the enhanced response to chemotherapy at secondary sites observed in Fasudil-primed conditions. Disruption of SRC signaling and actomyosin cytoskeleton dynamics with Fasudil may sensitize KPC cells to chemotherapy In line with the reported role of ECM-integrin outside-in signaling in cancer (47, 69), we assessed whether the integrin-SRC signaling axis is altered upon priming with Fasudil. Using a SRC-FRET biosensor ( fig.  S5A ) (70) in 3D organotypic matrices, we found that SRC activity is reduced after manipulation of the ECM with Fasudil ( fig. S5 , B and C) (70) . Intravital imaging in subcutaneous KPC tumors also confirmed inhibition of SRC signaling in response to Fasudil priming in vivo (fig. S5, D and E). This is in line with the recent role that SRC has been proposed to play in both sensitizing cancer cells to chemotherapy (71) (72) (73) (74) and driving ECM-dependent events in PC (75) (76) (77) . Additionally, ROCK inhibitors can induce mitotic defects (78-81), and we therefore assessed early-to-mid and late mitosis in KPC subcutaneous tumors. This revealed that although we do not see any significant change of cell proliferation or death upon Fasudil priming (Fig. 4E and fig. S3 , D and E), ROCK inhibition induces an accumulation of cells in late mitosis and multinuclear cells ( fig. S5, F and G) , thereby potentially making cells more responsive to subsequent treatment with antimicrotubule chemotherapy. Together, our data in cells from the KPC model suggest that priming delays PC progression in both primary and secondary sites. We therefore sought to translate our findings to patient-derived tumors.
Patient-derived models reveal potential for tailored, short-term priming strategy in PC Because PC is highly heterogeneous (29, 82), we next assessed whether fibrillar collagen abundance could influence tumor response to priming with Fasudil before chemotherapy. SHG analysis of PDX samples from the APGI cohort (29) allowed us to identify TKCC2 as an example of a "low ECM PDX" and TKCC5 as an example of a "high ECM PDX" (Fig. 8A) . Patient-derived cancer cell lines (PDCLs) isolated from the respective PDXs (29) were then subcutaneously reinjected into mice (Fig. 8B) . Subsequent SHG imaging revealed that reinjected PDCLs recapitulated many of the original features of the collagen matrix (Fig. 8B) , demonstrating the capacity of PDCLs to remodel the tissue and to "activate" host fibroblasts to maintain inherent features of the tumor.
To assess PDCL response to the priming regimen, we first established patient-personalized organotypic matrices, where cancer-associated fibroblasts (CAFs), "activated" by the respective patient-derived tumor cells in vivo, were isolated from PDXs, embedded in collagen, and characterized by IHC staining with pancytokeratin, a-smooth muscle actin, and fibroblast activation protein (figs. S6 and S7). After remodeling of the matrix by CAFs, matched patient-derived cancer cells were seeded on top of the contracted matrices (figs. S6, A and C, and S7, A and C), as previously performed with KPC cells (Figs. 2 and 3) . Priming with Fasudil impaired the ability of the "high ECM" TKCC5 CAFs to remodel collagen, as demonstrated by SHG analysis (fig. S6, B and D to F) , and resulted in decreased cancer cell invasion (fig. S6, G and H) and increased response to Gem/Abraxane treatment ( fig. S6, I and J). Conversely, priming had no effect on "low ECM" TKCC2 CAF-driven collagen contraction ( fig. S7 , B and D to F) and did not modify response to chemotherapy ( fig. S7, G and H) . This prompted us to assess TKCC2 and TKCC5 response to priming with Fasudil in live tumors.
PDCLs were engineered to express the CDK1-FRET biosensor, and in vitro FLIM-FRET measurements confirmed that the biosensor can distinguish changes in CDK1 activity in both lines (figs. S6, K and L, and S7, I and J), as previously achieved with KPC cells (fig. S2 ). CDK1-PDCLs were subcutaneously injected into mice, and when tumors were fully established (average tumor volume, 180 mm 3 , as previously described for KPC tumors; figs. S6M and S7K), mice were subjected to 3 days of priming with Fasudil before administration of Gem/Abraxane and intravital imaging ( figs. S6M and S7K, timelines) . Although SHG analysis demonstrated a reduction of fibrillar collagen abundance in the high ECM TKCC5 upon manipulation with Fasudil (Fig. 8C) , priming had no effect on the matrix of low ECM TKCC2 (Fig. 8C) . Intravital analysis of CDK1 activity in response to chemotherapy revealed that priming with Fasudil induces a robust increase of TKCC5 response to Gem/Abraxane in vivo (Fig. 8D, left) . A moderate improvement of TKCC2 response to chemotherapy was observed (Fig.  8D, right) , demonstrating a graded response to the priming strategy in relation to initial PDX collagen status (Fig. 8E) .
Last, given the enhanced response to priming found in the high ECM TKCC5 model, we assessed the long-term effects of priming on therapeutic response in an orthotopic patient-derived model. Orthotopic injections of TKCC5 cells were conducted, and primary tumors were allowed to grow until average in vivo imaging system (IVIS) luciferase signal reached 5 x 10 7 photons/s ( fig. S8A ). Mice were subjected to cycles of priming with Fasudil before administration of Gem/Abraxane until the experimental end point (Fig. 8F and fig. S8A ). Survival was increased by the priming regimen compared to treatment with Gem/ Abraxane alone (mean survival: Gem/Abraxane, 51 days; Fasudil priming and Gem/Abraxane, 75 days) (Fig. 8F) . Mice receiving Fasudil priming before Gem/Abraxane also had a reduced primary tumor burden at the ethical end point ( fig. S8B ). Time to detection of metastasis observed via whole-body IVIS imaging was also delayed by the priming regimen compared to control ( fig. S8, A and C) .
Finally, we created an in-house automated SHG tool to analyze the International Cancer Genome Consortium (ICGC) cohort of patient biopsy samples (231 ICGC samples) (Fig. 8G and fig. S8, D and E) . Although we found no significant differences in survival or clinicopathological variables with regard to bulk patient ECM content ( fig. S8F ), in line with recent work (10) , this rapid and label-free biopsy imaging approach could be used as a companion personalized biomarker for current stromal-based combination therapies in PC, where the initial amount of tumor ECM could guide whether a patient would be suitable for "transient" stromal intervention (Fig. 8, D to F) (12, 83) .
DISCUSSION
Combined therapies and multimodal targeting have improved outcomes in multiple cancers (84) , but little is known on how to streamline these methods to provide maximum benefit. Here, we demonstrate that transient priming of primary and secondary sites via ROCK inhibition improves chemotherapy efficacy and retards the onset of metastasis in PC.
Mechanoreciprocity and host tissue properties play a vital role in nascent tumors, from providing initial survival signals to driving cancer cell proliferation, invasion, and metastasis (85, 86) . Here, we use a combination of 3D in vitro and in vivo platforms with mouse-and patientderived PC cells to guide and optimize tissue manipulation scheduling in the context of Gem/Abraxane therapy. Our results suggest that shortterm inhibition of cellular tension in the whole tumor tissue before chemotherapy reduces cancer progression and improves response to treatment. Despite the distinct composition of the ECM in our different in vitro and in vivo models, our data reveal a similar effect in all settings, suggesting that this is a general phenomenon for multiple microenvironments. This suggests that depriving cancer cells of cues provided by the surrounding matrix at both primary and secondary sites renders them more sensitive to cytotoxic drugs, partly via impaired integrin signaling, as previously demonstrated in melanoma (67) . This is in line with our recent findings that inhibition of collagen cross-linking via antibody-targeted therapy against lysyl oxidase in combination with Gem effectively impaired PC progression (12) . ROCK inhibition also seems to induce accumulation of mitotic defects in vivo, potentially making cells more susceptible to subsequent chemotherapy (3). The molecular fingerprint of human PC is highly heterogeneous (29, 82) . High-throughput SHG analysis of the human ICGC cohort revealed heterogeneity in collagen profiles across patients. Using intravital monitoring of chemotherapy efficacy in patient-derived samples, we showed a graded response to Fasudil priming strategies relative to the initial fibrillar collagen profile in tissue biopsies. Our findings thereby suggest that high amounts of fibrillar collagen could potentially serve as a companion biomarker to identify patients who are likely to benefit from transient ECM manipulation before chemotherapy. This is in line with current clinical stroma-targeting therapies, where such companion biomarkers are being used for hyaluronic acid targeting, supporting matrix manipulation therapy in a subpopulation of patients (83) . Fine-tuned ECM-based stratification could therefore facilitate a more tailored therapeutic approach to matrix manipulation therapy in PC and could be used as an alternative to the "all patients" chronic stromal targeting approach in this disease.
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Although we demonstrate disruption of the physical properties of the ECM upon manipulation with Fasudil, we also reveal that repurposing Fasudil's clinical vasodilatory effects (28) through transient priming before chemotherapy improves short-term tumor blood perfusion and, thereby, drug delivery. This is in line with its current use for the treatment of cerebral vasospasm after subarachnoid hemorrhage in Japan (87-89) while avoiding any long-term toxic effects that could arise from chronic treatment (36, 39) . Therefore, targeting ECMdependent and ECM-independent changes in cancer appears to be an important advantage of transient ROCK inhibition compared to chronic ECM targeting alone (39, 90, 91) and warrants further consideration with regard to repurposing the off-patent drugs in PC (92) .
Monitoring the onset of hepatic micrometastasis revealed that manipulation of tissue at secondary sites impairs liver colonization. Analyses on CDMs and in the liver demonstrated that priming with Fasudil alters KPC cell attachment, coordinated movement, and malleable spread of the tumor emboli, potentially via changes of the mechanical and biochemical properties of the host ECM, thereby altering ECMcell interactions and durotaxis (93, 94) . Furthermore, the Rho-ROCK-LIMK pathway drives path generation by leading tumor cells (66, 95) , and hence, ROCK inhibition with Fasudil may inhibit path generation and coordinated cell movement of tumor cells in this context (95, 96) . Additionally, priming with Fasudil may decrease cell survival in the bloodstream via impaired tolerance to shear stress (97) . Whereas previous studies have reported conflicting findings on the effects of ROCK inhibition on cell invasion (98-100), short-term treatment with Fasudil did not show adverse effects, unlike chronic ROCK targeting. We also reveal that Fasudil priming impairs the ability of metastasized cells to create a fibrotic refuge, potentially enhancing their vulnerability to subsequent chemotherapy (67) . We propose that instead of completely ablating stroma-cancer cell feedback, transient priming of tissue by Fasudil before chemotherapy can impair cancer cell establishment, survival, growth, and spread at multiple sites in vivo while minimizing negative effects that may arise from chronic treatment.
Although Fasudil monotherapy or combinations with selected cardiovascular agents have previously been shown to be safe in humans by numerous large-scale studies (87) (88) (89) , this agent is yet to be combined with chemotherapies in the clinic. A phase 1 clinical trial would determine the safety of transient "priming" regimen with Fasudil before treatment with Gem/Abraxane in patients. Our study used patient TMA material from the ICGC cohort (82) , which is composed of largely early-stage tumors (I, IIa, and IIb) and hence does not equally cover the full spectrum of the disease. Validation studies would ideally include a cohort of more metastatic disease to fully appreciate the utility of our proposed SHG companion biomarker. Additionally, given the dual effects of Fasudil priming on both the ECM and the tumor vasculature, combination of both SHG and CD31-based biomarkers might further facilitate the identification of patients who could benefit from priming before chemotherapy.
Newer ROCK inhibitors such as K-115 (Ripasudil), which have recently entered the clinic for the treatment of glaucoma (101, 102) or are currently in the clinical testing pipeline, including phase 2 clinical trial for glaucoma (AMA0076) (103), or CCT129254 or AT13148, which reduce metastasis in other cancers (104) , could also have similar applications (105) . Patient presentation in PC ranges from early local invasion at the time of diagnosis to late metastatic disease (106) . We have demonstrated multisite benefits using priming in combination with standard-of-care therapy (summarized in fig. S9 ) and envision its potential use to treat PC at several stages.
MATERIALS AND METHODS
Study design
This study interrogates the effect of transient manipulation of tissue tension via ROCK inhibition on PC progression and response to Gem/ Abraxane. In vitro organotypic and CDM experiments were performed in independent biological triplicates, with three technical replicates per repeat and per treatment group. For in vivo experiments, numbers of mice used for each model are outlined in corresponding figures and figure legends. In vivo priming started when tumor volume reached 180 mm 3 (average size) or 7 × 10 5 photons/s (average IVIS signal). Mice for which tumor volume or IVIS signal was 10% lower or higher than the average value before enrollment were excluded from analysis.
FLIM-FRET analysis of CDK1 and SRC activity in vitro was conducted in >30 cells per group in three independent biological repeats. In vivo analysis of CDK1 and SRC was performed in 80 cells per mouse, with measurements in three subcellular areas per cell to generate an average value for CDK1 specifically, whereas measurements of lifetime in the whole cell (one value per cell) were performed for analysis of SRC activity.
IHC, SHG, picrosirius red, and GLCM analyses were conducted on three representative FOVs in organotypic matrices and CDMs and in five representative FOVs in subcutaneous xenograft and intrasplenic
S C I E N C E T R A N S L A T I O N A L M E D I C I N E | R E S E A R C H A R T I C L E
experiments. Metastatic burden, extravasation, and metastasis morphology in the liver were analyzed in serial sections (five sections per organ with a 100-mm step). Experimental end points for survival experiments were in compliance with Garvan Ethics Committee guidelines (13/17, 14/06, 14/11, and 16/13 protocols).
Statistical analysis
Unless stated otherwise, P values were determined by unpaired, nonparametric t test with Mann-Whitney U correction (comparison between two groups) or nonparametric ANOVA test with Holm-Sidak correction for multiple comparison (more than two groups). KaplanMeier curves were compared using a log-rank Mantel-Cox test. Exact P values for all figures are provided in table S1.
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